Going Public

We dosed the first patient in a Phase 1 clinical trial of our second product candidate, P-PSMA-101, in May 2020. Poseida completed a crossover financing round just prior to an initial public offering (IPO) in July 2020, going public on the Nasdaq under the ticker symbol PSTX. The company is currently listed on the Russell 2000 Index and the Nasdaq Biotech Index (NBI).